Company intelligence / Profile preview
Iperboreal Pharma
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
Iperboreal Pharma’s most advanced product is a glucose-sparing peritoneal dialysis solution that has reached Phase 3 clinical trials. The company’s approach uses novel osmotic agents such as L-carnitine and xylitol to reduce glucose exposure during peritoneal dialysis, aiming to improve biocompatibility and metabolic outcomes. Early clinical results suggest improved safety profiles and potential benefits in insulin resistance compared to traditional glucose-based solutions.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Small moleculeMedical deviceBiologic (for some solutions containing naturally occurring agents)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Iperboreal Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iperboreal Pharma.